FDA review of dupilumab for chronic spontaneous urticaria

Published Date: 13 Mar 2023

The FDA approval request for CSU is based on data from a pair of Phase 3 trials in two different populations.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Adding Chemo to Osimertinib Doubles PFS in Advanced NSCLC

2.

Non-small cell lung cancer patients who are ineligible for platinum-based chemotherapy benefit from atezolizumab monotherapy.

3.

GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium

4.

Mosunetuzumab in Follicular Lymphoma: Durable Responses and Manageable Safety

5.

Report provides global picture of wide inequalities in care for women's cancers


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot